References
- Ueda M, Misumi Y, Mizuguchi M, et al. SELDI-TOF mass. spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 2009;55(6):1223-7
- Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 1995;274(20):1627-9
- Schipper HM. Presymptomatic apolipoprotein E genotyping for Alzheimer’s disease risk assessment and prevention. Alzheimers Dement 2011;7(4):e118-23
- Hsiung GY, Sadovnick AD. Genetics and dementia: risk factors, diagnosis, and management. Alzheimers Dement 2007;3(4):418-27
- Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369(6):540-8
- Hauser PS, Narayanaswami V, Ryan RO. Apolipoprotein E: from lipid transport to neurobiology. Prog Lipid Res 2011;50(1):62-74
- OMIM. Available from: www.ncbi.nlm.nih.gov/omim
- Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7(2):180-4
- Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med 1996;47:387-400
- Uchida Y, Ito S, Nukina N. Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms. J Clin Lab Anal 2000;14(6):260-4
- Pereira LV, Dolphin PJ. Tryptic peptide analysis of the human apolipoprotein E isomorphs. Can J Biochem 1982;60(11):1032-42
- Wardell MR, Brennan SO, Janus ED, et al. Apolipoprotein E2-Christchurch (136 Arg – Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 1987;80(2):483-90
- Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Anal Biochem 2009;395(1):116-18
- Wang M, Chen J, Turko IV. 15N-labeled full-length apolipoprotein E4 as an internal standard for mass spectrometry quantification of apolipoprotein E isoforms. Anal Chem 2012;84(19):8340-4
- Nishimura M, Satoh M, Nishimura S, et al. Human apolipoprotein e resequencing by proteomic analysis and its application to serotyping. PLoS One 2014;9(1):e85356
- Simon R, Girod M, Fonbonne C, et al. Total ApoE and ApoE4 isoform assays in an Alzheimer’s disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 2012;11(11):1389-403
- Panza F, Solfrizzi V, Colacicco AM, et al. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer’s disease patients and centenarians. Neuroreport 2003;14(4):605-8
- Wang C, Yu JT, Wang HF, et al. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer’s disease. PLoS One 2014;9(2):e89041
- Vanitallie TB. Preclinical sporadic Alzheimer’s disease: target for personalized diagnosis and preventive intervention. Metabolism 2013;62(Suppl 1):S30-3
- Gandy S, Dekosky ST. APOE ε4 status and traumatic brain injury on the gridiron or the battlefield. Sci Transl Med 2012;4(134):134ed4